XOMA (US) LLC (XOMA) Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma Gangrenosum
6/13/2013 8:47:25 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BERKELEY, Calif., June 13, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has opened enrollment in a pilot study to determine gevokizumab's potential to treat acute inflammatory pyoderma gangrenosum. Pyoderma gangrenosum (PG) is one of the several rare diseases that are classified under the broader cluster of neutrophilic dermatoses. XOMA's pilot study is designed to enroll up to eight patients who are experiencing acute inflammatory PG. An inflammatory episode of PG is characterized by recently developed active ulcers and ulcer-related pain.
Help employers find you! Check out all the jobs and post your resume.